Guatemala LNS Non-Compliance: Automatic Registration Cancellation and 15-Day Market Withdrawal

1. Key takeaways

The Annex 2 note of NT 37 Versión 5-2016 prescribes one of the harshest consequences in the Guatemalan framework. For products subject to laboratory testing, if the conclusion of the National Health Laboratory (LNS) is “No Cumple” (does not comply with specifications), the sanitary registration of that product is automatically cancelled (automáticamente queda anulada), and the registration holder and the person responsible for the product must withdraw it from the market within a period not exceeding 15 days. There is no opportunity to correct or supplement the submission, and there is no discretionary room for the authority to weigh circumstances. The test result itself is the trigger, which means the only effective protection is upstream: ensuring that the sample submitted for testing genuinely represents the commercial product, and that batch quality is controlled so that a failure never occurs in the first place.

2. Legal basis

The provisions below define when testing applies, how samples are sealed, and what happens when the laboratory concludes that a product does not comply. The Annex 2 note is the operative rule on automatic cancellation, while the surrounding articles of NT 37 explain the testing categories and the documentation standards against which compliance is judged. Read as a set, they show that the testing regime is designed as a single chain: classification determines whether testing applies, sample sealing secures the evidence, and the Annex 2 note fixes the consequence of an adverse result.

3. Expert insights

Insight 1: “Automatic” is the heaviest word in this rule. The Annex 2 note uses the phrase “automáticamente queda anulada” — the cancellation does not require a separate administrative decision, because the laboratory conclusion itself triggers it. This stands in sharp contrast with the discretionary cancellations of Article 11, where the authority evaluates and decides. Companies should manage this at the production-planning and sample-preparation stages as an irreversible risk: once the sample fails, the consequence follows by operation of the rule, not by an act of grace, and no amount of post-hoc argument about sample handling or laboratory variance can reopen the registration on its own.

Insight 2: Responsibility falls on two parties, the registration holder and the responsible person. The note reads “el Propietario y el responsable del mismo quedarán obligados a retirarlo del mercado” — the registration holder (propietario) and the person responsible for the product (responsable) jointly bear the withdrawal obligation. Under NT 37 these two roles correspond to the holder described in Article 5.1.13 and the responsible professional described in Article 5.1.2. The allocation of withdrawal duties between the two roles should be written clearly into the agreements concluded at the registration stage, because after a failed test there is no time to negotiate who does what, and an ambiguous allocation converts directly into lost days.

Insight 3: The starting point of the 15 days, and the difficulty of execution, are underestimated. The note says only “en un tiempo no mayor de quince días” and does not specify when the period begins. As a practical estimate, the withdrawal should be launched on the very day the notification is received, because the 15 days must cover notifying the distribution chain, recovering stock, handling goods in transit and issuing stop-sale instructions to the channels, with no buffer remaining. Any delay in starting consumes time that the recovery logistics will need, so the first hours after notification matter more than any later effort.

Insight 4: Sample consistency is the only line of defence in front of this rule. Since the laboratory conclusion triggers cancellation directly, the only way to reduce the risk is to ensure that the sample submitted for testing is identical to the commercialised batches. Submitting better samples or special batches for testing merely postpones the risk from the review stage to the market surveillance stage, where the cost of failure is far higher: an automatic cancellation and a forced withdrawal rather than a request for additional information. The economics are one-sided: the saving made at the testing stage is trivial compared with the commercial value destroyed by a cancelled registration.

4. Practical recommendations

• Draw testing samples from commercialised batches and retain reserve samples, keeping batch numbers, production dates and retention records.
• Write the 15-day withdrawal into an executable contingency plan that specifies the notification chain, the recovery routes and the responsible individuals.
• State the allocation of withdrawal responsibilities between the registration holder and the responsible professional in the agreements made at the registration stage.
• Launch the withdrawal on the day the LNS notification is received, without waiting for further explanation.
• Establish batch-level quality traceability so that any questioned batch can be located and isolated quickly.

5. Verification checklist

• □ Testing sample batches consistent with commercialised batches and reserve samples retained
• □ 15-day withdrawal contingency plan written and responsible persons designated
• □ Allocation of responsibilities between registration holder and responsible professional written into agreements
• □ Withdrawal trigger set as the day the notification is received
• □ Batch quality traceability mechanism established

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Guatemalan market. Our team manages Ministry of Public Health and Social Assistance (MSPAS) registrations, coordinates import and distributor requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com